Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-25 @ 12:01 AM
Ignite Modification Date: 2025-12-25 @ 12:01 AM
NCT ID: NCT06974058
Eligibility Criteria: Inclusion Criteria: * Age: 18 to 75 years. * History of confirmed COVID-19 infection at least 6 months prior to the enrollment. * Persistent mild to moderate COVID-19 symptoms for at least 3 months post-acute infection. * Diagnosis of Long COVID-19 based on WHO criteria. * Symptom burden score of ≥25 at baseline (V0) on the COVID-19 Yorkshire Rehabilitation Scale (C19-YRS). * At least one symptom scoring between 1-7 on the C19-YRS. * Stable medical condition: No recent hospitalization (past 3 months) due to acute illness. * Willing and able to adhere to the study protocol, including follow-up visits, symptom reporting, and compliance with supplementation Exclusion Criteria: * Hypersensitivity or allergy to quercetin, curcumin, or any component of the supplement (Nasafytol®). * Severe, uncontrolled chronic illness (e.g., severe heart failure, chronic kidney disease requiring dialysis, severe liver disease). * Regular use of quercetin or curcumin supplements within the last 3 months. * Use of anticoagulants (e.g., warfarin, heparin, DOACs) due to potential anticoagulant effects of quercetin/curcumin. * Acute illness at the time of screening. * Pregnancy or breastfeeding. * Use of immunosuppressive medications or corticosteroids within the past month. * Significant psychiatric disorder that may interfere with study compliance.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 18 Years
Maximum Age: 75 Years
Study: NCT06974058
Study Brief:
Protocol Section: NCT06974058